Application:
1. Type 2 Diabetes Management:
- Blood Glucose Control: Tirzepatide, as a dual GIP and GLP-1 agonist, has the potential to enhance insulin secretion and reduce glucagon release, leading to improved blood glucose control.
- HbA1c Reduction: Tirzepatide has shown promising results in reducing glycated hemoglobin (HbA1c) levels, a key marker of long-term blood glucose control.
2. Weight Management:
- Obesity Treatment: Tirzepatide's dual action on GIP and GLP-1 receptors may lead to decreased appetite and increased feelings of fullness, making it a candidate for obesity treatment and weight management.
3. Cardiovascular Health:
- Cardiovascular Risk Reduction: Lik(e) other GLP-1 RAs, tirzepatide is being investigated for its potential cardiovascular benefits, such as reducing the risk of major adverse cardiovascular events (MACE) in individuals with type 2 diabetes and established cardiovascular disease.
4. Chronic Kidney Disease:
- Renal Benefits: Some GLP-1 RAs, including tirzepatide, have shown potential renal benefits, including reducing the risk of kidney disease progression, in certain populations with type 2 diabetes and chronic kidney disease.
5. Non-Alcoholic Fatty Liver Disease (NAFLD):
- Liver Health: Given its potential effects on metabolic parameters, tirzepatide is being explored for its role in improving liver health and managing non-alcoholic fatty liver disease.
6. Neurological and Cognitive Health:
- Neuroprotective Effects: Research is ongoing to explore the potential neuroprotective effects of tirzepatide and its implications for neurodegenerative diseases and cognitive health.
7. Inflammation and Immune System Modulation:
- Anti-Inflammatory Effects: Tirzepatide's actions on multiple metabolic pathways may have implications for reducing systemic inflammation, which is often associated with type 2 diabetes and related conditions.
8. Gastrointestinal Health:
- Gastrointestinal Motility: Tirzepatide's influence on gastrointestinal motility and function might have applications in managing conditions such as gastroparesis.
9. Potential Future Applications:
- Other Metabolic Disorders: Ongoing research is exploring tirzepatide's potential applications in other metabolic disorders, such as dyslipidemia and metabolic syndrome.
Related products:
<
|
Name
|
CAS
|
|
GHK-CU(1:1)
|
89030-95-5
|
|
GHK-CU(2:1)
|
49557-75-7
|
|
Tripeptide-1
|
72957-37-0
|
|
TYR-D-ALA-GLY-PHE-LEU
|
64963-01-5
|
|
Hexapeptide 9
|
1228371-11-6
|
|
mu-conotoxin
|
936616-33-0
|
|
L-Carnosine
|
305-84-0
|
|
Acetyl Pentapeptide-1
|
97530-32-0
|
|
Argireline
|
616204-22-9
|
|
Acetyl Octapeptide-3
|
868844-74-0
|
|
Palmitoyl Hexapeptide-12
|
171263-26-6
|
|
Pal-Tripeptide-1
|
147732-56-7
|
|
Palmitoyl Tripeptide-5
|
623172-56-5
|
|
Palmitoyl tetrapeptide-7
|
221227-05-0
|
|
Palmitoyl Pentapeptide
|
214047-00-4
|
|
Biotinyl-GHK tripeptide
|
299157-54-3
|
|
Acetyl Tetrapeptide-5
|
820959-17-9
|
|
Myristoyl Pentapeptide-17
|
959610-30-1
|
|
Myristoyl Hexapeptide-16
|
959610-54-9
|
|
Palmitoyl Tripeptide-8
|
936544-53-5
|
|
Acetyl tetrapeptide 15
|
928007-64-1
|
|
Tetrapeptide-30
|
1036207-61-0
|
|
Nonapeptide-1
|
158563-45-2
|
Our factory
FAQs
Q1: How can I get the price?
A1: We usually quote within 6 hours after we get your inquiry -If you are very urgent to get the price, please email us or contact us in other ways so that we can offer you a quote.
Q2: Can I buy samples placing orders?
A2: Yes.Please feel free to contact us.
Q3: What is your lead time?
A3: It depends on the order quantity and the season you place the order.Usually we can ship within 3-5 days for quantity,and about 15 days for large quantity.
Q4: What is the shipping method?
A4: It could be shipped by sea,by air or by express(EMS,UPS,DHL,TNT,FEDEX and ect).Please confirm with us before placing orders.
Q5: How do you make our business long-term and good relationship?
A5:
1.We keep good quality and competitive price to ensure our customers benefit ;
2. We respect every customer as our friend and we sincerely do business and make friends with them,no matter where they come from.
